Key result
Magnetic resonance angiography demonstrated marked reduction in neovascularity in all 6 chemotherapy responders and persistent or increased neovascularity in all 3 non-responders.
Why the study?
Does magnetic resonance angiography (MRA) accurately assess neovascularity and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma?
Population
9 patients with osteogenic (n=7) or Ewing sarcoma (n=2)
Design
Case_series
Authors
Loading...
MRA may noninvasively track sarcoma chemotherapy response; leaves open larger validation before routine use.
Observational (n=9)
Does magnetic resonance angiography (MRA) accurately assess neovascularity and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma?
MRA can non-invasively assess tumoral neovascularity in vivo and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma.
Lang et al. (1996) conducted an observational in Osteogenic or Ewing sarcoma (n=9). Magnetic resonance angiography (MRA) was evaluated on Chemotherapy-induced changes in neovascularity compared to histologic tumor necrosis. Magnetic resonance angiography demonstrated marked reduction in neovascularity in all 6 chemotherapy responders and persistent or increased neovascularity in all 3 non-responders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: